# HONEST PROJECT ASSESSMENT: Should We Continue or Stop?

**Date:** December 24, 2025  
**Purpose:** Critical evaluation of fusion model performance and research direction  
**Status:** FRANK RESEARCH-LEVEL ANALYSIS

---

## EXECUTIVE SUMMARY: THE BRUTAL TRUTH

**YOUR CONCERN IS VALID.**

The fusion models are **NOT** consistently outperforming single-modality baselines. In many experiments, **MRI-Only actually beats Late Fusion and Attention Fusion**.

This is a **RED FLAG**, but not necessarily a project failure.

Let me break down what's happening, why, and what you should do about it.

---

## PART 1: THE PATTERN OF FAILURE (What The Data Shows)

### 1.1 OASIS In-Dataset (Reference Performance)

**OASIS WITHOUT MMSE (Realistic Early Detection):**
```
- MRI-Only:           AUC = 0.770 ¬± 0.080
- Clinical-Only:      AUC = 0.743 ¬± 0.082
- Late Fusion:        AUC = 0.794 ¬± 0.083  [+2.4% over MRI]
- Attention Fusion:   AUC = 0.790 ¬± 0.109  [+2.0% over MRI]
```

**ANALYSIS:** Fusion WORKS on OASIS, but gains are marginal (2-3%).  
**PROBLEM:** High variance (¬±0.08-0.11) makes the improvement barely significant.  
**VERDICT:** Weak positive signal. Not convincing evidence.

---

### 1.2 ADNI Level-1 (The "Honest" Early Detection Scenario)

**ADNI LEVEL-1 (MRI + Age + Sex, NO cognitive scores):**
```
- MRI-Only:           AUC = 0.583 (CI: 0.47-0.68)
- Late Fusion:        AUC = 0.598 (CI: 0.49-0.70)  [+1.5% over MRI]
- Attention Fusion:   (Not explicitly reported, likely similar)
```

**ANALYSIS:**
- Performance is **DISMAL** (barely better than random = 0.50)
- Fusion adds only +1.5% AUC
- 95% confidence intervals **OVERLAP** ‚Üí improvement not statistically significant

**PROBLEM:** The model is struggling to learn ANYTHING meaningful.  
**VERDICT:** **FAILURE**. This is not publishable as "early detection."

---

### 1.3 Cross-Dataset Transfer (The Complete Breakdown)

**EXPERIMENT A: OASIS (Source) ‚Üí ADNI (Target)**
| Model | Source AUC | Target AUC | Drop | Notes |
|-------|------------|------------|------|-------|
| **MRI-Only** | 0.814 | **0.607** | -0.207 | ‚Üê **BEST** (least collapse) |
| Late Fusion | 0.864 | 0.575 | -0.289 | ‚Üê **WORSE than MRI-Only!** |
| Attention Fusion | 0.826 | 0.557 | -0.269 | ‚Üê **WORST** generalization! |

**EXPERIMENT B: ADNI (Source) ‚Üí OASIS (Target)**
| Model | Source AUC | Target AUC | Drop | Notes |
|-------|------------|------------|------|-------|
| MRI-Only | 0.686 | 0.569 | -0.117 | |
| **Late Fusion** | 0.734 | **0.624** | -0.110 | ‚Üê **BEST** (clinical helps here) |
| Attention Fusion | 0.713 | 0.548 | -0.165 | ‚Üê **UNSTABLE**, severe collapse |

**CATASTROPHIC FINDING:**
- ‚ùå In Exp A, MRI-Only (0.607) **BEATS** both fusion models (0.575, 0.557)
- ‚ùå Attention Fusion is **BRITTLE**: it collapses hardest in both directions
- ‚ùå Adding clinical features **HURTS** transfer robustness in 50% of cases

**VERDICT:** **FUSION IS ACTIVELY HARMFUL** in cross-dataset scenarios.

---

### 1.4 Level-2 (The "Circular" Upper-Bound with MMSE/CDR-SB)

**ADNI LEVEL-2 (MRI + MMSE + CDR-SB + Age + APOE4 + Education):**
```
- Late Fusion:        AUC = 0.988
```

**ANALYSIS:** Near-perfect performance, BUT this is **CIRCULAR**.  
MMSE and CDR-SB are cognitive scores that directly measure the outcome.  
This proves the model **CAN** learn, but doesn't validate early detection.

**VERDICT:** Not usable for research claims. Only confirms model isn't broken.

---

## PART 2: WHY IS FUSION FAILING? (Root Cause Analysis)

### 2.1 THE FUNDAMENTAL PROBLEM: Feature Quality Mismatch

**MRI Features:**
- 512 dimensions (high-dimensional, pretrained ResNet18)
- Rich spatial information from brain structure
- Contains subtle patterns learned from ImageNet transfer

**Clinical Features (Level-1):**
- **2 dimensions** (Age, Sex) or **2 dimensions** (Age, Education)
- **EXTREMELY WEAK** signal for early detection
- Age is a **CONFOUNDER** (correlates with both dementia and brain atrophy)

**THE MISMATCH:**
```
512 strong features + 2 weak features = 514 features
But the 2 weak features ADD MOSTLY NOISE.
```

**Result:** Fusion dilutes the MRI signal instead of enhancing it.

---

### 2.2 DIMENSION IMBALANCE (The 512 vs 2 Problem)

**Late Fusion Architecture:**
```
MRI Encoder:      512 ‚Üí 32 (compression ratio: 16:1)
Clinical Encoder:   2 ‚Üí 32 (EXPANSION ratio: 1:16!)
```

The **2D clinical features** are **UPSAMPLED to 32D**, creating:
- 30 dimensions of **RANDOM NOISE** (learned from dropout and initialization)
- Only 2 dimensions carry actual signal

When concatenating `[32-dim MRI] + [32-dim Clinical]`:
- You get **64-dim fusion vector**
- But **~30 of those dims are clinical encoder noise**
- This **DILUTES** the MRI representation

**Result:** Classifier sees `[32 strong + 30 weak + 2 real_clinical]` = **worse than `[32 strong]`**.

---

### 2.3 SMALL DATASET + HIGH VARIANCE (Overfitting)

**Sample Sizes:**
- OASIS usable: **N = 205** (164 train, 41 test)
- ADNI: **N = 629** (503 train, 126 test)

With only **164-503 training samples**:
- Attention Fusion learns **dataset-specific gating patterns**
- These patterns **DON'T generalize** (see cross-dataset collapse)
- More parameters (fusion weights, gates) = more overfitting risk

**Evidence:**
- High variance in OASIS (¬±0.109 for Attention)
- Cross-dataset collapse worse for Attention than Late Fusion
- MRI-Only is **SIMPLER** ‚Üí generalizes better

**Result:** Complexity **HURTS** when data is scarce.

---

### 2.4 AGE AS A CONFOUNDER (Not a True Feature)

Age correlates with:
- Brain atrophy (normal aging)
- Dementia risk (older = higher risk)
- Dataset collection bias (ADNI recruits older adults)

But Age does **NOT** encode **DISEASE-SPECIFIC** pathology.

When fusion models "use" Age:
- They're learning **"older ‚Üí probably impaired"** (a shortcut)
- **NOT** learning **"structural damage ‚Üí impaired"** (the real signal)

**Result:** Age adds **bias**, not biology.

---

### 2.5 CLINICAL FEATURES ARE PROXIES, NOT BIOMARKERS

**What we want:**
- Clinical features that reveal **HIDDEN disease mechanisms**
- (e.g., genetic markers like APOE4, cerebrospinal fluid biomarkers)

**What we have:**
- **Age:** General aging marker (not disease-specific)
- **Sex:** Weak epidemiological correlate (women slightly higher AD risk)
- **Education:** Protective factor hypothesis (cognitive reserve) but weak signal

These are **POPULATION-LEVEL** correlates, not **INDIVIDUAL-LEVEL** biomarkers.

**Result:** Clinical features don't add complementary information to MRI.

---

## PART 3: WHAT THIS MEANS FOR YOUR RESEARCH

### 3.1 THE GOOD NEWS (Yes, There Is Some)

‚úÖ **Your data cleaning is IMPECCABLE.**
- No leakage, proper splits, honest evaluation
- This is **RARE** in ML research. Most papers have hidden leaks.

‚úÖ **You documented the FAILURE honestly.**
- Level-1 (honest) vs Level-2 (circular) separation is publication-worthy
- Showing MMSE inflates AUC 0.60‚Üí0.99 is a valuable negative result

‚úÖ **Cross-dataset experiments are RIGOROUS.**
- Most papers only report in-dataset results (easy to inflate)
- Your transfer results reveal **TRUE** generalization (spoiler: it's bad)

‚úÖ **You have a COMPLETE narrative.**
- "We tried fusion. It failed. Here's why." is a **valid thesis chapter**

---

### 3.2 THE BAD NEWS (The Harsh Reality)

‚ùå **Your Level-1 results are NOT competitive with literature.**
- Published dementia detection papers report **0.80-0.95 AUC**
- Your **0.58-0.60 AUC** looks like failure by comparison
- **BUT:** Most lit results use MMSE/CDR-SB (circular) or single-site data

‚ùå **Fusion models are NOT providing value.**
- Marginal gains (1.5-2.4%) that aren't statistically significant
- Break down in cross-dataset transfer
- Reviewers will ask: **"Why use fusion if it doesn't help?"**

‚ùå **The problem is HARD.**
- Early detection from MRI alone is genuinely difficult
- Cognitive reserve, normal aging, and heterogeneity confound signals
- No amount of architecture tweaking will fix weak features

‚ùå **Clinical features (Age, Sex) are TOO WEAK.**
- You need **BETTER** clinical data (biomarkers, genetic, CSF proteins)
- But OASIS/ADNI baseline don't have comprehensive biomarker panels

---

## PART 4: SHOULD YOU CONTINUE OR STOP?

### OPTION 1: STOP and Publish as Negative Result / Methodological Critique

**WHEN TO CHOOSE THIS:**
- You're on a deadline (thesis defense in 3-6 months)
- You don't have access to better datasets
- You want to graduate with what you have

**WHAT TO PUBLISH:**

**Title:** *"On the Difficulty of Early Dementia Detection: A Rigorous Cross-Dataset Evaluation Reveals Limited Fusion Benefits"*

**Key Claims:**
1. Honest early detection (no MMSE) achieves only **0.60 AUC** (vs 0.99 circular)
2. Fusion models **fail to outperform MRI-only** in cross-dataset transfer
3. Clinical features (Age, Sex) provide **negligible complementary signal**
4. Most literature results are **inflated** by circular features and single-site data

**Contribution:**
- Methodological rigor (data cleaning documentation)
- Negative result that challenges field assumptions
- Cross-dataset robustness benchmark

**VENUE:**
- Medical image analysis methodology journals (e.g., *Medical Image Analysis*)
- Workshop papers (MICCAI workshops accept honest negative results)
- Thesis chapter (definitely defensible)

**PROS:**
- ‚úÖ You can finish **NOW**
- ‚úÖ Negative results are valuable (if rigorous)
- ‚úÖ Your documentation is publication-ready

**CONS:**
- ‚ùå Won't get into top-tier venues (MICCAI, IPMI want positive results)
- ‚ùå May face skeptical reviewers ("just get better features")
- ‚ùå Career-wise, positive results open more doors

---

### OPTION 2: PIVOT to Better Clinical Features (3-6 Month Investment)

**WHEN TO CHOOSE THIS:**
- You have 6+ months before deadline
- You can access additional ADNI data (beyond baseline CSV)
- You want a competitive positive result

**WHAT TO DO:**

**Step 1:** Extract **RICHER** clinical features from ADNIMERGE:
- CSF biomarkers (AŒ≤42, tau, p-tau) [available in ADNIMERGE]
- Genetic markers (APOE4, polygenic risk scores) [available]
- Neuropsychological battery (beyond just MMSE) [available]
- Vascular risk factors (hypertension, diabetes) [available]

**Step 2:** Create NEW **Level-1.5** (Biomarker-Informed, Not Circular):
- MRI (512) + CSF (3) + APOE4 (1) + Vascular (2-3) = **518-519 features**
- These are **BIOLOGICAL** markers, not cognitive proxies
- Still "early detection" (biomarkers available at baseline)

**Step 3:** Retrain and re-evaluate:
- Expect **0.65-0.75 AUC** (realistic improvement from biomarkers)
- Fusion should work **BETTER** (biomarkers are complementary to MRI)
- Cross-dataset: use OASIS-3 (has CSF data) or AIBL dataset

**EXPECTED OUTCOME:**
- 0.70-0.75 AUC in honest early detection (competitive with lit)
- Fusion gains increase to **5-8%** (statistically significant)
- Story becomes: *"Biomarkers + MRI fusion works, demographics alone don't"*

**EFFORT:** 3-6 months (data extraction, retraining, new experiments)

**PROS:**
- ‚úÖ Competitive positive result
- ‚úÖ Publishable in top-tier venues
- ‚úÖ Fusion models become justified (biomarkers add value)

**CONS:**
- ‚ùå Requires additional data work
- ‚ùå Risk: biomarkers might STILL not help enough
- ‚ùå Some biomarkers (CSF) are invasive (limits early detection claim)

---

### OPTION 3: PIVOT to Longitudinal Prediction (3-6 Month Investment)

**WHEN TO CHOOSE THIS:**
- You have 6+ months
- You want to use FULL ADNI longitudinal data
- You're willing to change the research question

**NEW RESEARCH QUESTION:**
*"Can baseline MRI + clinical features predict **FUTURE cognitive decline**?"*  
(Different from "detect current impairment")

**WHAT TO DO:**
- Use ADNI longitudinal data (you currently discard m06, m12, etc.)
- Predict: **"Will this CN subject convert to MCI within 2 years?"**
- Labels: Baseline CN ‚Üí Future MCI (Converter=1, Stable=0)

**WHY THIS MIGHT WORK BETTER:**
- Larger sample size (use all CN subjects with follow-up)
- Clearer signal (predicting **CHANGE**, not current state)
- Fusion becomes valuable (MRI shows early damage, clinical shows risk)

**EXPECTED OUTCOME:**
- **0.70-0.80 AUC** (research has shown this is feasible)
- Fusion gains: **5-10%** (clinical features predict conversion risk)
- Publishable as "early prediction of conversion"

**EFFORT:** 3-6 months (data restructuring, survival analysis, new experiments)

**PROS:**
- ‚úÖ Uses data you already have (ADNI longitudinal)
- ‚úÖ Easier problem (conversion prediction works better than detection)
- ‚úÖ Fusion models justified (temporal dynamics matter)

**CONS:**
- ‚ùå Different research question (not early DETECTION)
- ‚ùå Requires learning survival analysis / time-to-event methods
- ‚ùå Thesis might need restructuring

---

### OPTION 4: DEEP DIVE into MRI Architecture (6-12 Month Investment)

**WHEN TO CHOOSE THIS:**
- You have 12+ months
- You want to push MRI performance higher
- You're interested in deep learning architecture research

**HYPOTHESIS:**
*"ResNet18 (pretrained on natural images) might not be optimal for MRI. Can we learn better representations?"*

**WHAT TO DO:**

**Self-supervised learning on MRI:**
- Contrastive learning (SimCLR) on all OASIS+ADNI scans
- Masked autoencoder (MAE) for MRI reconstruction
- Train on 1000+ unlabeled scans, then fine-tune for dementia

**3D CNNs instead of 2.5D:**
- Use Med3D (medical 3D pretrained models)
- Requires GPU cluster (memory-intensive)

**Transformer-based models:**
- Vision Transformer (ViT) adapted for 3D medical imaging
- Swin Transformer for hierarchical features

**EXPECTED OUTCOME:**
- MRI-Only might reach **0.70-0.75 AUC** (up from 0.58-0.60)
- Fusion gains become clearer (better MRI baseline)
- Publishable as "better MRI representations for dementia"

**EFFORT:** 6-12 months (architecture search, hyperparameter tuning, ablations)

**PROS:**
- ‚úÖ Addresses root problem (weak MRI features)
- ‚úÖ Publishable in ML conferences (new architecture)
- ‚úÖ Could be PhD-worthy contribution

**CONS:**
- ‚ùå Very time-consuming
- ‚ùå Requires significant compute (GPU cluster)
- ‚ùå Risk: might still not work (small sample size limits deep learning)

---

## PART 5: MY HONEST RECOMMENDATION

### SCENARIO A: You Need to Finish Soon (< 6 Months)

**‚Üí CHOOSE OPTION 1: Publish as rigorous negative result**

**THESIS TITLE:**  
*"Cross-Dataset Evaluation of Multimodal Fusion for Early Dementia Detection: A Methodological Critique"*

**NARRATIVE:**
1. Establish honest baseline (Level-1: 0.60 AUC without circular features)
2. Show literature inflation (Level-2: 0.99 AUC with MMSE proves circularity)
3. Demonstrate fusion failure (cross-dataset: MRI-Only beats fusion)
4. Explain root causes (dimension imbalance, weak clinical features)
5. Recommend future work (biomarkers, longitudinal, better architectures)

**DEFENSE ANGLE:**
> *"My thesis demonstrates that current fusion approaches fail under rigorous evaluation. This is a valuable contribution because it challenges field assumptions and establishes honest benchmarks for future work."*

---

### SCENARIO B: You Have Time and Want Competitive Results (6+ Months)

**‚Üí CHOOSE OPTION 2: Get better clinical features (biomarkers)**

**ACTION PLAN:**
- **Week 1-2:** Extract CSF, APOE4, vascular features from ADNIMERGE
- **Week 3-4:** Create Level-1.5 dataset (MRI + biomarkers, NO cognitive scores)
- **Week 5-8:** Retrain all models, run cross-validation
- **Week 9-10:** Cross-dataset experiments (if you get OASIS-3 or AIBL data)
- **Week 11-12:** Write up results

**EXPECTED THESIS OUTCOME:**  
*"Biomarker-Informed Multimodal Fusion for Early Dementia Detection"*
- Level-1.5: **0.70-0.75 AUC** (competitive, honest)
- Fusion gains: **5-8%** (significant)
- Publishable in *Medical Image Analysis* or similar

---

### SCENARIO C: You're Genuinely Curious About the Science

**‚Üí HYBRID APPROACH: Publish negative result NOW, continue as extended work**

**IMMEDIATE:**
1. Write up current results as workshop paper / preprint
2. Submit to MICCAI workshop or arXiv
3. Use as thesis chapter

**THEN (if time/interest):**
4. Try Option 2 (biomarkers) as Chapter 2
5. Compare: *"Fusion with demographics fails, fusion with biomarkers works"*
6. This becomes a **STORY**: *"What makes fusion work? Feature quality, not architecture."*

---

## PART 6: WHY YOUR RESULTS AREN'T "BAD" - THEY'RE HONEST

### MOST PAPERS IN THIS FIELD ARE LYING (Unintentionally, but Still)

They report **0.85-0.95 AUC** by:
- ‚ùå Using MMSE/CDR-SB as features (circular reasoning)
- ‚ùå Training and testing on **SAME site** (no cross-dataset validation)
- ‚ùå Cherry-picking best hyperparameters on test set (data snooping)
- ‚ùå Not documenting exclusions (hidden sample selection)

**YOUR 0.60 AUC is closer to the TRUTH than their 0.90 AUC.**

### REAL-WORLD CLINICAL DEPLOYMENT

If you took those "0.90 AUC" models and deployed them in a hospital:
- ‚ùå They would **FAIL** (cross-site, different scanner, different protocols)
- ‚úÖ Your **0.60 AUC** is more realistic estimate of real performance

### YOUR CONTRIBUTION

You showed that **honest early detection is HARD**.  
You documented **WHY** (weak features, fusion failure, dataset shift).  
You provided **clean data and reproducible code**.

**This IS valuable, even if the AUC numbers aren't exciting.**

---

### WHAT SEPARATES "BAD RESEARCH" FROM "GOOD NEGATIVE RESULT"

**BAD RESEARCH:**
- ‚ùå Got bad results due to bugs or poor methodology
- ‚ùå Can't explain why it failed
- ‚ùå No lessons learned

**YOUR RESEARCH:**
- ‚úÖ Got honest results from rigorous methodology
- ‚úÖ Can explain root causes (dimension imbalance, weak features)
- ‚úÖ Clear path forward (biomarkers, longitudinal, better architectures)

‚Üí **This is GOOD research with negative results, not bad research.**

---

## PART 7: CONCRETE NEXT STEPS (What to Do Tomorrow)

### DECISION TREE

**1. Ask yourself: "When do I need to finish?"**
- < 6 months: Go with **Option 1** (publish negative result)
- 6-12 months: Go with **Option 2** (get biomarkers)
- 12+ months: Consider **Option 4** (new architectures)

**2. Ask yourself: "What do I want from this research?"**
- Graduate ASAP: **Option 1**
- Competitive publication: **Option 2**
- Learn deep learning: **Option 4**
- Make real clinical impact: **Option 3** (longitudinal prediction)

**3. Ask your advisor: "Would you support a negative result thesis?"**
- If yes: You're safe with **Option 1**
- If no: You need to try **Option 2** or **3**

---

### IF YOU CHOOSE OPTION 1 (My Recommendation for Quick Finish)

**TOMORROW:**
1. Start writing thesis chapter with current results
2. Frame as methodological critique (not failure)
3. Emphasize rigor (use `DATA_CLEANING_AND_PREPROCESSING.md` verbatim)

**THIS WEEK:**
4. Create publication-ready figures (ROC curves, cross-dataset comparison)
5. Write abstract emphasizing "honest evaluation reveals fusion limitations"
6. Identify target venue (MICCAI workshop, *Medical Image Analysis*)

**NEXT MONTH:**
7. Submit workshop paper or preprint
8. Continue writing thesis
9. Prepare defense slides

**THESIS DEFENSE ANGLE:**
> *"I challenged common assumptions in dementia detection research by:*
> 1. *Removing circular features (MMSE)*
> 2. *Testing cross-dataset generalization*
> 3. *Showing that fusion fails under rigorous conditions*
> 
> *My contribution is methodological rigor, not algorithmic novelty."*

**Reviewers CANNOT argue with honest negatives if methodology is sound.**  
**Your methodology IS sound.**

---

### IF YOU CHOOSE OPTION 2 (Better Clinical Features)

**TOMORROW:**
1. Download full `ADNIMERGE.csv` (you have it)
2. Check for CSF biomarkers: `ABETA`, `TAU`, `PTAU` columns
3. Check for genetic data: `APOE4` column
4. Check for vascular: `HYPERTENSION`, `DIABETES` columns

**THIS WEEK:**
5. Write script to merge these into your existing train/test CSVs
6. Create new Level-1.5 feature files (MRI + biomarkers)
7. Verify: **NO** cognitive scores (MMSE, CDRSB) in Level-1.5

**NEXT MONTH:**
8. Retrain all three models (MRI-Only, Late Fusion, Attention)
9. Run cross-validation on ADNI
10. Measure if fusion NOW provides 5-8% gain (statistically significant)

**EXPECTED OUTCOME:**
- ‚úÖ If biomarkers help: You get publishable positive result
- ‚úÖ If biomarkers DON'T help: You strengthened the negative result  
  (tried everything, still didn't work ‚Üí even more convincing)

---

## FINAL VERDICT: TO CONTINUE OR TO STOP?

### CONTINUE IF:
- ‚úì You have 6+ months
- ‚úì You can access biomarker data easily
- ‚úì You want a competitive positive result
- ‚úì Your advisor expects algorithmic contribution

### STOP (and publish negative) IF:
- ‚úì You need to finish in < 6 months
- ‚úì You're burnt out and want to move on
- ‚úì You value rigorous methodology over flashy results
- ‚úì You're okay with workshop-level publication

### HYBRID (recommended):
- ‚úì Package current results as Chapter 1 / Workshop paper **NOW**
- ‚úì Try biomarkers as extended work if time permits
- ‚úì This way you have **guaranteed thesis content + potential upside**

---

## MY PERSONAL TAKE

Your fusion models failed because you gave them **TERRIBLE clinical features** (just Age and Sex). 

That's like asking someone to improve a 512-ingredient recipe by adding 2 random spices - **it won't help, might even hurt**.

**BUT:** This isn't **YOUR** failure. It's the **FIELD'S** problem.
- Most dementia datasets don't have rich baseline biomarkers
- Early detection from imaging alone is genuinely hard
- Fusion architectures can't fix fundamentally weak features

**YOUR WORK IS VALUABLE** because it **DOCUMENTS** this problem rigorously.

If you can get better features (biomarkers), try it.  
If not, publish the negative result and move on.

**Either way, you did GOOD RESEARCH.**  
Don't let low AUC numbers fool you.

---

## BOTTOM LINE

Your results "bother you" because you're comparing to **inflated literature**.

Compare to **HONEST baselines** instead:
- Early detection without MMSE: **0.60-0.70 AUC is NORMAL**
- Cross-dataset transfer: **20-30% AUC drop is EXPECTED**
- Fusion with weak features: **marginal gains (1-3%) is REALISTIC**

**You're not failing. The task is just HARD.**

Document it honestly, graduate, and move on to something more tractable.

---

## END OF ASSESSMENT

**Author's Note:** I wrote this to be brutally honest because sugarcoating won't help you make the right decision. Your work is rigorous and valuable. The results are disappointing because the problem is hard and the features are weak, not because you did something wrong. You have a complete, defensible thesis either way. Choose the path that fits your timeline and career goals.

**Good luck.** üéì
